Acrivon Therapeutics, Inc. (ACRV)
NASDAQ: ACRV · Real-Time Price · USD
1.450
-0.010 (-0.68%)
At close: Nov 13, 2026, 4:00 PM EST
1.480
+0.030 (2.07%)
After-hours: Nov 13, 2026, 7:04 PM EST
Acrivon Therapeutics Stock Forecast
Stock Price Forecast
According to 7 analysts polled by S&P Global, Acrivon Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $11.5. The average 1-year stock price forecast is 693.10% higher than the current stock price, while the lowest is $7.00 (+382.76%) and the highest is $19 (+1,210.34%).
Price Target: $11.5 (+693.10%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Acrivon Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '26 | Jun '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 4 | 4 | 4 | 4 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Reiterates $8 | Buy | Reiterates | $8 | +451.72% | Nov 11, 2026 |
| Maxim Group | Maxim Group | Buy Maintains $7 | Buy | Maintains | $7 | +382.76% | Nov 10, 2026 |
| Oppenheimer | Oppenheimer | Buy Maintains $8 | Buy | Maintains | $8 | +451.72% | Aug 13, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Maintains $19 | Buy | Maintains | $19 | +1,210.34% | Aug 13, 2026 |
| Gabelli No rating | Gabelli | Buy Initiates $8 | Buy | Initiates | $8 | +451.72% | Jun 15, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.82
from -2.02
EPS Next Year
-1.54
from -1.82
EPS and Forward PE are based on non-GAAP adjusted numbers.